Lipid nanoparticles (LNPs) have become a key delivery platform for nucleic acid-based therapies, mRNA vaccines, and other novel biologics. However, developing and manufacturing LNPs is not a one-size-fits-all process. Their performance depends heavily on the characteristics of the payload, target tissue, and production scale. A customized LNP service provides an end-to-end solution—from sequence design to GMP-ready manufacturing—addressing delivery challenges while improving efficiency, reproducibility, and project outcomes.
LNP performance is influenced by lipid composition, particle size, surface properties, and encapsulation efficiency. Different payloads behave differently: certain mRNA sequences may reduce encapsulation due to secondary structures, while some proteins or small molecules may destabilize particles due to hydrophobicity or charge distribution. Standard formulations often fail to meet these diverse needs, leading to particle aggregation, low encapsulation, and unstable formulations. Optimization strategies focus on sequence and payload design to improve compatibility, lipid formulation and process parameters using microfluidics and gradient mixing for uniform particle size and high encapsulation, and surface modification such as PEGylation or targeting ligands to enhance stability and targeting. These approaches align the carrier and payload for optimal performance from the start.
LNP development involves multiple rounds of formulation screening and scale-up. Without a structured approach, repeated experiments can waste time and resources. A customized service improves efficiency by:
Early sequence-to-formulation matching : Computational prediction and small-scale screening identify stable and effective combinations before large-scale investment.
Modular process design : Microfluidic formulation, ultrafiltration, and particle control are implemented as reproducible modules, allowing experience to be leveraged across projects.
Data-driven iterative optimization : Real-time monitoring of particle characteristics and encapsulation efficiency provides a quantitative basis for scalable process adjustments.
This approach minimizes material use, reduces personnel effort, and shortens the timeline from concept to GMP manufacturing.
Predictable outcomes are critical for projects moving toward scaled production. Generic workflows often produce batch-to-batch variability, affecting particle size, encapsulation, and stability. A customized LNP service ensures predictability through standardized process control, including:
Precise formulation and process parameters : Lipid combinations and flow ratios are optimized to match payload characteristics and maintain batch consistency.
Scale-up validation : Small-scale success is verified through stepwise scale-up, ensuring microfluidic mixing and concentration processes translate reliably.
Comprehensive characterization : Particle size, encapsulation, and long-term stability are assessed with high-throughput methods to confirm consistent product quality.
These measures provide a continuous, controlled path from laboratory development to GMP-ready production, reducing uncertainty and supporting smooth project progression.
Fig.1 LNP workflow: Sequence design, formulation, and GMP production (BOC Sciences Original).
In LNP delivery systems, the nucleic acid sequence is not merely a "passenger" carrying genetic information—it is a central determinant of formulation stability, delivery efficiency, and biological activity. High-quality sequence design can reduce reliance on carrier load, minimizing cytotoxicity while significantly enhancing protein expression or gene silencing efficiency. Well-optimized sequences also improve encapsulation efficiency, particle uniformity, and storage stability, providing a solid foundation for downstream process scale-up and manufacturing. The table below summarizes key sequence features and their impact on LNP critical quality attributes, offering actionable guidance for early-stage optimization.
Table.1 Relationship Between Nucleic Acid Sequence Design and LNP Critical Quality.
| Sequence Design Dimension | Direct Impact on LNP / Biological Activity | Expert Optimization Strategies and Best Practices |
| Codon Optimization | Affects mRNA secondary structure stability, influencing folding compactness and charge distribution within LNP | Use algorithms to balance translation rate and secondary structure, avoiding excessively strong hairpins to optimize spatial constraints during encapsulation |
| Chemical Modification | Alters nucleic acid charge density and hydrophobicity, impacting electrostatic interactions with cationic/ionizable lipids and complex stability | Establish correlations between modification rate (e.g., percentage of modified nucleotides) and N/P ratio to minimize immune recognition while maintaining high encapsulation efficiency |
| UTR Design | Determines intracellular mRNA half-life and ribosome loading, affecting peak protein expression and duration | Introduce stabilizing elements (e.g., species-specific alpha-globin sequences) to extend effective expression time within target tissues |
| Poly-A Tail | Tail integrity is critical for LNP degradation and particle uniformity | Prefer template-encoded Poly-A to ensure sequence consistency, improving downstream TFF purification yield and product purity |
| Sequence Length | Longer sequences increase sensitivity to shear; long RNAs (e.g., self-amplifying RNA) are prone to physical breakage or incomplete encapsulation during microfluidic mixing | Optimize microfluidic channel geometry and reduce total flow rate to minimize shear stress on extended nucleic acid chains |
Sequence optimization is not a simple codon replacement—it is a careful balance of translation efficiency, immune evasion, and LNP delivery performance. Secondary structure thermodynamics are critical: overly stable structures can hinder ribosome binding, while overly loose structures are susceptible to nuclease degradation. Within LNPs, nucleic acid folding determines interaction surface area with lipid bilayers, affecting encapsulation and particle uniformity. Design strategies guide nucleic acids toward compact conformations that favor efficient encapsulation.
Chemical modifications such as N1-methylpseudouridine are widely used to reduce recognition by innate immune receptors while improving stability and lipid interactions.
UTR customization is equally important. Selection of 5' and 3' UTRs can enhance ribosome binding, increase protein output at lower LNP doses, and improve in-formulation stability.
Sequence design must align with process development to reduce technical risk during scale-up.
Sequence length and shear sensitivity: Long sequences (e.g., self-amplifying RNA or large plasmids) experience higher shear forces during microfluidic mixing. Early-stage design should evaluate nucleic acid flexibility and match appropriate channel geometry and flow rates.
Impurity profile prediction: Regions prone to secondary structure formation can generate higher levels of double-stranded RNA (dsRNA) during in vitro transcription. Thermodynamic modeling can help minimize such impurities, reducing downstream purification burden.
Poly-A tail consistency: Tail length uniformity is essential. Template-encoded Poly-A ensures consistent folding within LNPs, improving batch-to-batch reproducibility for particle size, encapsulation, and stability.
By integrating sequence design with process strategy, research teams can establish a reliable formulation foundation early, reducing iterative optimization efforts and enabling an efficient, controlled path for LNP development.
From initial nucleic acid design to GMP-compliant lipid nanoparticle production, we provide flexible, client-focused solutions for efficient drug delivery.
LNP development is not simply a matter of mixing lipids with nucleic acids; it is a precisely controlled molecular assembly process. An ideal formulation must strike a delicate balance between protecting the nucleic acid payload, enabling efficient intracellular release, and maintaining biocompatibility.
LNPs are typically composed of four core lipid components, and the choice and molar ratios of these components directly determine the particle's physicochemical properties and biological behavior:
Ionizable Lipids : These form the core of the LNP. They carry a positive charge under acidic conditions during formulation to encapsulate nucleic acids, remain neutral at physiological pH to reduce toxicity, and regain a positive charge in the acidic endosome to promote membrane fusion and endosomal escape. Customized services select ionizable lipids with specific pKa values to optimize delivery to particular tissues, such as the lung or spleen.
Helper Lipids : Typically DSPC or DOPE, helper lipids stabilize the bilayer structure. Adjusting the saturation or shape (e.g., from cylindrical to cone-shaped) can significantly modulate membrane fluidity and fusion efficiency at the cellular surface.
Cholesterol : Acts as a "molecular glue," filling gaps between lipids to regulate membrane rigidity and reduce permeability. Cholesterol derivatives, such as oxidized cholesterol, can alter the in vivo distribution and transfection patterns of LNPs.
PEG-Lipids : Polyethylene glycol (PEG) chains control particle size and circulation time. PEG density and chain length (typically 0.5–2%) form a steric barrier that prevents aggregation and slows rapid clearance by the immune system.
Optimizing these components and their ratios is critical. Excess ionizable lipid can increase encapsulation but may raise cytotoxicity, while excessive PEG-lipid can reduce cellular uptake. High-throughput screening combined with microfluidic mixing allows rapid evaluation of different lipid combinations for particle size, zeta potential, encapsulation efficiency, and stability, yielding reproducible, optimized formulations.
After successful formulation in the laboratory, a set of preclinical indicators is used to evaluate the translation potential of the LNP. Optimization focuses on converting in vitro performance into effective in vivo delivery:
Biodistribution : Standard LNPs tend to accumulate in the liver. Adjusting lipid ratios or introducing specific permanent cationic lipids (e.g., SORT technology) can modulate interactions with plasma proteins such as ApoE, enabling targeted delivery to the lung, spleen, or immune cells.
Immune Response Balance : Excessive immune activation can interfere with mRNA expression. Optimizing PEG shedding rates or selecting low-inflammatory ionizable lipids can maintain adjuvant effects while minimizing systemic cytokine induction.
Physicochemical Stability : Key preclinical metrics include zeta potential changes in different buffers, particle size rebound after storage, and nucleic acid integrity. Accelerated stability studies provided by custom services can guide formulation storage strategies.
Table.2 Trends in LNP Performance Based on Common Lipid Ratio Adjustments.
| Adjustment | Effect on Particle Size | Effect on Transfection Efficiency | Potential Challenges |
| Increase PEG-lipid proportion | Significantly reduces particle size | Often decreases transfection efficiency | May create a "PEG shielding" effect, hindering endosomal escape |
| Increase N/P ratio | Produces more compact particles | Initial transfection efficiency improves | May increase cytotoxicity and inflammatory response |
| Replace unsaturated helper lipid | Minimal effect on size | Improves membrane fusion and payload release | Lipids are prone to oxidation; antioxidant strategies required |
| Introduce targeted ligand lipid | Slightly increases size | Enables tissue-specific accumulation | High ligand density may lead to rapid receptor-mediated clearance |
The development and manufacturing of LNPs depend not only on optimized formulations and process parameters but also on rigorous analytical characterization and quality control. A comprehensive analytical framework allows early detection of potential issues such as particle aggregation, incomplete encapsulation, or formulation instability, enabling corrective optimization before scaling up. Systematic characterization ensures that LNPs meet expected criteria for particle size, encapsulation efficiency, zeta potential, and nucleic acid integrity, providing reliable data to support downstream process scale-up and application. Customized services typically integrate analytical characterization with process development, creating a closed-loop optimization between formulation, process, and critical quality attributes (CQAs), which reduces development risk and ensures consistent, high-quality LNP products.
The physicochemical properties of LNPs directly influence their behavior in vitro and in vivo, including delivery efficiency, particle stability, and batch-to-batch consistency. Comprehensive characterization provides insights into internal structure, surface properties, and thermodynamic behavior, guiding formulation refinement. Key characterization parameters include:
Particle Size and Distribution : Average particle size and polydispersity index (PDI) are critical for determining biodistribution and cellular uptake efficiency. Microfluidic preparation can achieve highly uniform particle sizes, but verification using dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA) is essential to ensure consistency. Long-term monitoring of size distribution can also predict aggregation trends during storage and transport.
Zeta Potential : Surface charge influences particle stability and interactions with biomolecules, such as plasma proteins or non-specific adsorption. Electrophoretic light scattering (ELS) allows quantitative measurement of zeta potential, evaluating electrostatic stability and potential aggregation risks, and guiding PEGylation or surface modification strategies.
Structural Integrity and Morphology : Transmission electron microscopy (TEM) and cryogenic electron microscopy (Cryo-EM) enable direct observation of particle shape, core-shell structure, and uniformity. This information is critical for optimizing lipid composition and process parameters to improve stability and payload release profiles.
Thermal Stability and Storage Performance : Differential scanning calorimetry (DSC) and related thermal analysis methods assess lipid phase behavior and overall LNP thermal stability. These data support storage condition selection, cold-chain management, and lyophilization strategies, ensuring long-term reproducibility of particle properties.
By employing these physicochemical characterization techniques, research teams can identify potential formulation issues early, optimize lipid ratios and process parameters, reduce batch variability, and ensure long-term stability and consistency.
Comprehensive quantitative analysis is essential to guarantee LNP quality. Each critical attribute requires reliable measurement techniques:
Particle Size Analysis : DLS or NTA provides average particle size and PDI, supporting formulation optimization and process adjustments while enabling batch-to-batch and long-term stability assessment.
Surface Charge Measurement : Zeta potential evaluation predicts potential aggregation or sedimentation under different conditions, guiding PEGylation or surface modification strategies.
Encapsulation Efficiency (EE) : Fluorescent dyes, radiolabels, or high-performance liquid chromatography (HPLC) are used to quantify the proportion of nucleic acid or drug payload encapsulated, ensuring reproducibility of active molecule loading and maximizing delivery efficiency.
Nucleic Acid Integrity : Capillary electrophoresis (e.g., Fragment Analyzer) measures nucleic acid degradation, ensuring the payload remains intact and biologically active throughout formulation and storage.
Stability Assessment : Monitoring particle size, zeta potential, and encapsulation efficiency under different buffer conditions, temperatures, and storage durations provides data to optimize formulation preservation and predict long-term performance.
Table.3 Core LNP Characterization Parameters and Standard Evaluation Metrics.
| Parameter | Common Technique | Key Focus | Ideal Quality Target (mRNA-LNP) |
| Average Particle Size | Dynamic Light Scattering | Tissue penetration and cellular uptake | 60–120 nm (depending on target tissue) |
| Polydispersity Index (PDI) | DLS | Batch consistency and stability | ≤ 0.15 |
| Encapsulation Efficiency (EE%) | Fluorescent dye assay (Triton X-100) | Nucleic acid payload utilization | ≥ 90% |
| Surface Charge | Electrophoretic Light Scattering | Stability and membrane interaction | Near-neutral at pH 7.4 (-5 to +5 mV) |
| Nucleic Acid Integrity | Capillary Electrophoresis (Fragment Analyzer) | Ensure intact payload | ≥ 80% intact |
Systematic physicochemical and functional characterization allows research teams to establish relationships between key quality attributes and process parameters, providing a quantifiable and controllable development path for LNPs and reliable data for scale-up.
Transitioning from milligram-scale laboratory preparation to gram-scale quantities required for preclinical studies or GMP production is one of the stages most prone to "performance gaps" in LNP development. Scale-up is not simply a matter of proportionally enlarging equipment; it is a complex engineering process involving fluid dynamics, thermodynamics, and interfacial chemistry. Variables such as flow rates, shear forces, mixing energy, and solvent removal all have significant impacts on particle physical-chemical properties and functional performance.
In bench-scale experiments, researchers often use microfluidic chips or small syringe pumps for rapid screening and formulation optimization. At pilot scale, the main challenge is maintaining the physical consistency of the mixing process to ensure that particle uniformity, encapsulation efficiency, and stability are preserved at larger volumes.
Translation of the Mixing Mechanism : In small-scale preparation, nucleic acids and lipids achieve uniform contact within microseconds, resulting in narrow particle size distributions (low PDI). During scale-up, maintaining this uniformity requires predictable correspondence of Reynolds number (Re) across different equipment scales. High-throughput microfluidic platforms or impingement-based mixing methods (e.g., T-junction or IMI) allow higher total flow rates (TFR) while keeping nucleic acids and lipids in rapid, uniform contact, preventing local aggregation or uneven self-assembly.
Solvent Exchange and Concentration : As preparation volume increases, traditional dialysis methods become insufficient. Tangential flow filtration (TFF) is central at pilot scale. Optimizing shear rate and transmembrane pressure (TMP) enables efficient removal of organic solvents like ethanol and concentration of LNPs, while minimizing particle aggregation or structural disruption. TFF also allows scalable handling of multi-liter volumes while maintaining batch consistency.
Sterile Filtration and Pre-Filtration : At larger scales, LNP formulations are typically sterilized via 0.22 μm filtration. Without sufficient assessment of particle stability at small scale, scale-up can result in filter clogging or particle deformation under pressure. Introducing carrier proteins or excipients during pilot runs can enhance particle rigidity and flexibility, improving filtration recovery and operational reliability.
Successful technology transfer to CMC (Chemistry, Manufacturing, and Controls) teams relies on a thorough understanding of process boundaries and critical parameters.
Defining Critical Process Parameters : During scale-up, it is essential to identify which variables must remain fixed. For example, the flow rate ratio (FRR) between aqueous and organic phases is a key CPP. Even minor deviations at multi-liter flow rates can cause sharp drops in encapsulation efficiency or altered particle size. Other CPPs include total flow rate, shear rate, temperature, and transmembrane pressure, all of which must have quantifiable operational ranges.
Material Consistency : Laboratory-grade lipid or nucleic acid materials may contain trace impurities, which can be amplified at scale and affect particle uniformity or stability. Technology transfer requires strict raw material quality standards, including lipid purity, oxidation index, and nucleic acid sequence integrity.
Digital Monitoring for Batch Consistency : Real-time particle size monitoring (e.g., online DLS) and automated fluid control minimize operator error. This shift from manual preparation to programmatic production ensures that pilot-scale batches maintain the same physical-chemical properties as small-scale formulations, providing reliable reference data for downstream development.
Table.4 Key Variables and Scale-Up Challenges in LNP Production.
| Process Step | Critical Parameter | Common Scale-Up Issue | Optimization Strategy / Best Practice |
| Microfluidic Mixing | Flow Rate Ratio and Total Flow Rate | Local turbulence causing increased particle size or high PDI | Use geometrically scaled-up chips; maintain consistent mixing energy; match Reynolds number across scales |
| Organic Solvent Removal | Diavolumes (DV) | Residual ethanol affecting lipid stability | Perform ≥10-fold buffer exchange via TFF; optimize TMP and shear rate |
| Formulation Concentration | Transmembrane Pressure | Particle aggregation at high concentration | Introduce temperature-controlled circulation; reduce viscosity and thermal degradation; monitor particle size |
| Sterile Filtration | Filter Flux | Filter clogging due to insufficient particle deformability | Conduct filterability testing at pilot scale; optimize lipid composition for rigidity and flexibility |
By applying these scale-up strategies and optimization approaches, research teams can maintain key quality attributes of LNP formulations during pilot production, ensuring a smooth transition from laboratory to larger-scale manufacturing while providing a robust foundation for subsequent production expansion.
During LNP program execution, R&D teams often encounter multiple challenges: varying compatibility between nucleic acid sequences and formulations, difficulty in precisely controlling particle size and surface charge, and uncertainty when translating in vitro results into consistent performance. Efficient LNP development services go beyond experimental execution by integrating sequence design, formulation development, analytical characterization, and process optimization into a unified workflow. This approach enables clients to obtain reproducible and scalable outcomes more quickly. Our services are built on a problem-oriented, data-driven framework. Through modular workflows and customized technical strategies, we help shorten development timelines, reduce trial-and-error costs, and establish a scalable technical foundation at early project stages. To support global research teams in overcoming delivery challenges, we structure complex development logic into four core service modules:
Table.5 One-Stop LNP Technology Service Platform and Core Offerings.
Different nucleic acid types (mRNA, siRNA, circRNA, etc.) and delivery objectives require distinct LNP formulations. Standard formulations often cannot simultaneously optimize encapsulation efficiency, expression level, and stability. Customized lipid screening improves particle performance at the molecular level. We systematically evaluate combinations of ionizable lipids, helper lipids, cholesterol derivatives, and PEG-lipids to build a data model linking lipid structure, physicochemical properties, and functional performance. Optimization strategies include:
Ionizable lipid screening: Adjusting pKa values and lipid tail structures to improve nucleic acid encapsulation and endosomal release.
Helper lipid optimization: Selecting lipids with different saturation levels and molecular shapes to balance membrane stability and fusion efficiency.
PEG-lipid ratio tuning: Maintaining delivery efficiency while preventing aggregation and minimizing PEG shielding effects.
Cholesterol derivative evaluation: Modifying membrane rigidity and fluidity to improve particle stability and expression consistency.
Through high-throughput formulation screening combined with machine-learning analysis, optimal formulation windows can be identified quickly, providing reliable parameters for downstream scale-up.
Particle size and surface charge are key determinants of LNP delivery efficiency and stability. Oversized particles may limit tissue penetration and cellular uptake, while undersized particles can reduce encapsulation efficiency. Deviations from near-neutral surface charge may lead to aggregation or nonspecific interactions. Our technology platform enables predictable control of particle size and charge by precisely managing mixing energy, flow-rate ratios, and solvent environments. Key approaches include:
Microfluidic precision mixing: Adjusting total flow rate and flow rate ratio to achieve narrow size distribution and low PDI.
Buffer optimization: Controlling pH and ionic strength to stabilize surface charge and reduce aggregation risk.
Real-time particle monitoring: Using online DLS and related tools to track particle size dynamically and provide rapid process feedback.
This closed-loop control approach significantly improves batch consistency, ensuring particle size and charge remain within defined target ranges.
In vitro evaluation is an essential tool for predicting LNP performance. Systematic cellular uptake and release studies help identify formulation bottlenecks and guide optimization. Our multi-layer testing platform includes:
Cellular uptake analysis: Using fluorescently labeled nucleic acids or lipids with flow cytometry and confocal imaging to evaluate uptake efficiency and intracellular localization across cell types.
Endosomal release assessment: Applying pH-sensitive probes or reporter systems to analyze release efficiency and identify rate-limiting steps.
Expression kinetics and stability testing: Monitoring expression duration and degradation rates to refine lipid formulation and sequence design.
These data help establish structure-function relationships early in development, enabling rapid identification of high-potential formulations and reducing repeated experimental cycles.
